Best Biologics / mAb CDMOs in Europe
· updated as new inspection, certificate, and trial data enters the platform
10
CDMOs tracked
10
Fully scored
5
With FDA records
22
FDA inspections
71
EMA/MHRA GMP certs
2
Warning letters
Biologics CDMOs manufacture monoclonal antibodies, fusion proteins, and other large molecules in mammalian (typically CHO) cell culture. It is the largest and most mature segment of contract manufacturing, spanning early clinical supply through multi-thousand-litre commercial production.
Selecting a biologics CDMO turns on bioreactor scale and modality fit (mAb, bispecific, fusion protein), titer and cell-line strategy, fill-finish, and — above all — a clean regulatory record at commercial scale. The rankings below score each CDMO on FDA inspection history, EMA/MHRA GMP certification, clinical-program activity, and capacity.
FDA inspection outcomes across these CDMOs: 5 NAI (no action), 16 VAI (voluntary action), 1 OAI (official action). Leading inspection & GMP sites: Germany (18), Italy (18), United States (17), Denmark (17), UNITED KINGDOM (13).
Last updated 2026-09-01. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
MK
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
|
81.8 | 98.7 | 2 insp · 2 GMP | — | 22 programs |
| 2 |
FD
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
|
84.8 | 100.0 | 0 insp · 23 GMP | 0 programs | |
| 3 |
RB
Richter BioLogics
Hamburg, Germany
|
82.9 | 100.0 | 0 insp · 9 GMP | — | 0 programs |
| 4 |
EF
Eurofins CDMO
Planegg, DE · San Diego, CA
|
81.6 | 100.0 | 5 insp · 0 GMP | — | 0 programs |
| 5 |
CD
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
|
81.1 | 98.9 | 4 insp · 10 GMP | — | 0 programs |
| 6 |
BR
BioReliance (Merck)
Glasgow, UK · Rockville, MD
|
80.2 | 97.1 | 4 insp · 8 GMP | — | 0 programs |
| 7 |
PG
ProBioGen
Berlin, DE
|
78.1 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 8 |
BP
BSP Pharmaceuticals
Latina, Italy
|
70.5 | 83.6 | 7 insp · 14 GMP | — | 0 programs |
| 9 |
SI
Simtra BioPharma Solutions
Bloomington, IN · Halle, DE
|
65.7 | 73.3 | 0 insp · 1 GMP | — | 0 programs |
| 10 |
HP
HIPRA Biotech Services
Amer, Spain
|
63.0 | — | — | — | 0 programs |
What to evaluate in a Biologics / mAb CDMO
Scale & bioreactor fit
Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct.
Cell line & process development
Ask whether the CDMO offers its own expression platform/cell line or works from yours, and how process development and tech transfer are handled.
Regulatory track record
Biologics programs heading to BLA/MAA need a strong commercial-scale inspection history. Cross-check FDA 483s, warning letters, and EMA/MHRA GMP coverage — all shown above.
Drug substance to drug product
Confirm whether the CDMO covers fill-finish and formulation in-house or coordinates a separate site, which affects timelines and comparability.
EMA and MHRA regulatory considerations for European-manufactured programs
European manufacturing for biopharma programs typically requires EMA-recognized GMP certification (via the EudraGMDP database) for EU material and MHRA GMP certification for UK material — post-Brexit, these are separate credentials even for CDMOs operating in both. The Signal Score's Quality Compliance pillar weighs EMA + MHRA GMP certificate density directly, so European CDMOs with dense certification typically rank higher on this pillar. Sponsors should verify certificate coverage for the specific manufacturing activity (drug substance vs drug product, dosage form) at the specific facility being considered — GMP certificates are activity-scoped, not blanket.
QP release requirements and how they affect CDMO selection
Every batch of medicinal product supplied to the EU market must be released by a Qualified Person (QP) — a specific regulatory role with statutory responsibility. This adds a process step (and typically a specific QP-service arrangement) that US-only manufacturing does not require. CDMOs with European operations either have in-house QPs (typical for larger diversified players) or coordinate with external QP services. For sponsors running EU trials or supplying EU commercial markets, this is a non-negotiable requirement to plan for. Individual CDMO profile pages capture facility-level detail; QP arrangements specifically are usually confirmed at RFP stage rather than published.
Which European CDMOs also cover FDA (US) regulatory geography?
European CDMOs with US FDA inspection history — indicating US regulatory posture — are candidates for sponsors running programs in both jurisdictions. The Signal Score's Quality Compliance pillar includes FDA inspection classifications, so a European CDMO with a strong FDA record typically ranks higher on that pillar than a European-only competitor. Cross-check with the US region ranking — CDMOs appearing in both rankings have demonstrated regulatory posture across both jurisdictions, which reduces tech-transfer risk for global programs.
Biologics / mAb CDMOs — Frequently Asked Questions
Who are the top Biologics / mAb CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Biologics / mAb CDMOs include Merck KGaA / MilliporeSigma (CDMO), FUJIFILM Diosynth Biotechnologies, Richter BioLogics. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Biologics / mAb CDMOs have FDA inspection records?
CDMO Signal tracks 5 Biologics / mAb CDMOs with FDA inspection records and 71 EMA/MHRA GMP certificates across the group.
What should I look for in a biologics CDMO?
Match bioreactor scale and modality (mAb, bispecific, fusion protein) to your program, confirm cell-line and process-development support, and prioritize a clean FDA and EMA/MHRA record at the scale you'll commercialize at.
What is the difference between a biologics CDMO and a cell or gene therapy CDMO?
Biologics CDMOs make large molecules (antibodies, proteins) in bioreactors at litre-to-thousands-of-litre scale. Cell and gene therapy CDMOs make living cells or viral vectors in much smaller, often per-patient batches under different containment and analytics.
Related modalities